PRTO Proteon Therapeutics, Inc. gains 17% Jan 23, 2018

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. It develops vonapanitase, a recombinant human elastase, which is in two Phase III clinical trials in patients with chronic kidney disease undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis; has completed a Phase I/II clinical trials for the treatment of patients undergoing arteriovenous graft placement; and has completed Phase I clinical trial for the treatment of symptomatic peripheral artery diseases. The company was founded in 2001 and is headquartered in Waltham, Massachusetts. http://www.priceseries.com/trade/PRTO-Proteon-Therapeutics-Inc-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2018010920180123.html